Featured Research

from universities, journals, and other organizations

Intranasal corticosteroid treatment appears beneficial for children with obstructive sleep apnea

Date:
June 20, 2011
Source:
JAMA and Archives Journals
Summary:
Using a fluticasone furoate nasal spray for treatment of obstructive sleep apnea in children appears to reduce production of certain inflammatory cell proteins that may play a role in development of obstructive sleep apnea, according to a new study.

Using a fluticasone furoate nasal spray for treatment of obstructive sleep apnea in children appears to reduce production of certain inflammatory cell proteins that may play a role in development of obstructive sleep apnea, according to a report in the June issue of Archives of Otolaryngology -- Head & Neck Surgery, one of the JAMA/Archives journals.

"Obstructive sleep apnea syndrome is characterized by prolonged partial upper airway obstruction and/or intermittent complete obstruction with disruption of normal ventilation during sleep and normal sleep patterns," the authors write as background information in the study. It is estimated that obstructive sleep apnea syndrome (OSAS) occurs in 2 percent to 3 percent of children and can have a negative effect on overall quality of life. According to the authors, previous research has suggested a role for inflammation in OSAS, including increased release of certain cytokines and the presence of inflammatory cytokines.

To determine the effect of intranasal corticosteroid therapy on inflammatory cytokines (non-antibody proteins secreted by cells that act as mediators between cells) in adenoid tissues in children with OSAS, Rania Esteitie, M.D., and colleagues from The University of Chicago Medical Center and Pritzker School of Medicine, conducted a randomized, prospective exploratory study of 24 children ages 2 to 12 years who were undergoing adenotonsillectomy (surgical removal of the tonsils and adenoids) for OSAS that had been documented by polysomnography.

Children were randomized into one of two groups: treatment (n=11) or no treatment (n=13). The 11 children in the treatment group received 55g (microgram or mcg; equal to one millionth of a gram) of fluticasone furoate nasal spray (an intranasal corticosteroid) once daily for two weeks while the 13 children in the no-treatment group received no intranasal treatment. All children included in the analysis underwent adenotonsillectomy two weeks after initiation of treatment. The main outcome of the study was to determine the number of T-regulatory cells (specialized cells that act to suppress activation of the immune system) as well as levels of various cytokine receptors in both groups.

After the adenotonsillectomy, the authors weighed the removed adenoids from children in both groups to determine if treatment had worked to reduce the size of the tissue, but they found no significant difference in adenoid weight between the two groups.

The authors found that the treatment group had reduced levels of spontaneous IL-6 (a type I cytokine receptor that regulates cell growth and differentiation) production. The IL-6 cytokine is secreted by T-regulatory cells and induces cell growth differentiation in certain cells. The authors also note that it is an important predictor of cardiovascular risk and mortality. The treatment did not appear to have reduced levels of any other cytokine receptor examined, nor was there a significant difference in the number of T-regulatory cells produced in each group.

"In this study, we show reduction of IL-6, a proinflammatory cytokine, in adenoid tissue obtained from children with obstructive sleep apnea syndrome treated with fluticasone furoate nasal spray," the authors conclude. "This reduction could contribute to the clinical efficacy of this class of medications in the treatment of childhood obstructive sleep apnea syndrome."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. Esteitie, J. Emani, S. Sharma, D. L. Suskind, F. M. Baroody. Effect of Fluticasone Furoate on Interleukin 6 Secretion From Adenoid Tissues in Children With Obstructive Sleep Apnea. Archives of Otolaryngology - Head and Neck Surgery, 2011; 137 (6): 576 DOI: 10.1001/archoto.2011.86

Cite This Page:

JAMA and Archives Journals. "Intranasal corticosteroid treatment appears beneficial for children with obstructive sleep apnea." ScienceDaily. ScienceDaily, 20 June 2011. <www.sciencedaily.com/releases/2011/06/110620161210.htm>.
JAMA and Archives Journals. (2011, June 20). Intranasal corticosteroid treatment appears beneficial for children with obstructive sleep apnea. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/06/110620161210.htm
JAMA and Archives Journals. "Intranasal corticosteroid treatment appears beneficial for children with obstructive sleep apnea." ScienceDaily. www.sciencedaily.com/releases/2011/06/110620161210.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins